Biosplice Therapeutics has 3 close competitors: Neuralink, Oura Health, Life Biosciences.
Sector, valuation and status for each competitor.
A private valuation and a public market cap share one column; each row names its basis and date.
Biosplice Therapeutics
Neuralink
Oura Health
Life BiosciencesBiosplice Therapeutics (formerly Samumed) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics based on alternative pre-mRNA splicing and Wnt pathway modulation, with its most advanced program in osteoarthritis.
Biosplice Therapeutics competes with 3 companies here: Neuralink, Oura Health, Life Biosciences.
Biosplice Therapeutics was last valued at $12B (post-money, Apr 2021). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The closest biopharmaceutical — regenerative medicine / alternative pre-mrna splicing therapeutics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Biosplice Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $12B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
